The deal lets patients with prescriptions get Lilly medicines without leaving Hims & Hers, widening its weight-care service. Hims says it has never sold compounded versions of Lilly’s drugs, but the story gives no estimate of added sales.
Keeping care and medicine access in one place could make Hims & Hers more useful to people seeking weight treatment. It says it has never sold compounded versions of Lilly’s drugs and will avoid them. Third-quarter results are due Monday, so this story does not show whether the deal has brought in more sales.
The partnership gives Lilly another route to patients through a large telehealth platform. U.S. Zepbound sales rose 48% to $5.3 billion and Foundayo sales were $184 million, though lower realized Zepbound prices partly limited the increase.
Follow Hims & Hers Health Inc. (HIMS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HIMS